RT Journal Article
SR Electronic
T1 Deep learning-driven risk-based subtyping of cognitively impaired individuals
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.08.21267495
DO 10.1101/2021.12.08.21267495
A1 Romano, Michael F.
A1 Zhou, Xiao
A1 Balachandra, Akshara R.
A1 Jadick, Michalina F.
A1 Qiu, Shangran
A1 Nijhawan, Diya A.
A1 Joshi, Prajakta S.
A1 Lee, Peter H.
A1 Smith, Maximilian J.
A1 Paul, Aaron B.
A1 Mian, Asim Z.
A1 Small, Juan E.
A1 Chin, Sang P.
A1 Au, Rhoda
A1 Kolachalama, Vijaya B.
YR 2021
UL http://medrxiv.org/content/early/2021/12/09/2021.12.08.21267495.abstract
AB Quantifying heterogeneity in Alzheimer’s disease (AD) risk is critical for individualized care and management. Recent attempts to assess AD heterogeneity have used structural (magnetic resonance imaging (MRI)-based) or functional (Aβ or tau) imaging, which focused on generating quartets of atrophy patterns and protein spreading, respectively. Here we present a computational framework that facilitated the identification of subtypes based on their risk of progression to AD. We used cerebrospinal fluid (CSF) measures of Aβ from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (n=544, discovery cohort) as well as the National Alzheimer’s Coordinating Center (NACC) (n=508, validation cohort), and risk-stratified individuals with mild cognitive impairment (MCI) into quartiles (high-risk (H), intermediate-high risk (IH), intermediate-low risk (IL), and low-risk (L)). Patients were divided into subgroups utilizing patterns of brain atrophy found in each of these risk-stratified quartiles. We found H subjects to have a greater risk of AD progression compared to the other subtypes at 2- and 4-years in both the discovery and validation cohorts (ADNI: H subtype versus all others, p < 0.05 at 2 and 4 years; NACC: H vs. IL and LR at 2 years, p < 0.05, and a trend toward higher risk vs. IH, and p < 0.05 vs. IH, and L risk groups at 48 months with a trend toward lower survival vs. IL). Using MRI-based neural models that fused various deep neural networks with survival analysis, we then predicted MCI to AD conversion. We used these models to identify subtype-specific regions that demonstrate the largest levels of atrophy-related importance, which had minimal overlap (Average pairwise Jaccard Similarity in regions between the top 5 subtypes, 0.25±0.05 (± std)). Neuropathologic changes characteristic of AD were present across all subtypes in comparable proportions (Chi-square test, p>0.05 for differences in ADNC, n=31). Our risk-based approach to subtyping individuals provides an objective means to intervene and tailor care management strategies at early stages of cognitive decline.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was supported by grants from the Karen Toffler Charitable Trust, the Michael J Fox Foundation, the Lewy Body Dementia Association, the Alzheimers Drug Discovery Foundation, the American Heart Association (20SFRN35460031), the National Institutes of Health (R21-CA253498, RF1-AG062109, RF1-AG072654, U19-AG065156, P30-AG066515, R01-NS115114, K23-NS075097, U19-AG068753 and P30-AG013846), and the Hariri Institute for Computing and Computational Science & Engineering at Boston University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study involves only openly available human data, which can be obtained from the Alzheimers Disease Neuroimaging Initiative and the National Alzheimers Coordinating Center. Links: http://adni.loni.usc.edu and https://naccdata.org.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at http://adni.loni.usc.edu and https://naccdata.org.